These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Letter: International cooperation in drugs must be a simplification, not a complication]. Thrane O Nord Med; 1974 Feb; 89(2):35-6. PubMed ID: 4820743 [No Abstract] [Full Text] [Related]
4. [Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency]. Theilade MD Ugeskr Laeger; 2005 May; 167(20):2146-50. PubMed ID: 15987069 [No Abstract] [Full Text] [Related]
5. [The "third party" in the pharmaceutical industry]. Karrer E Boll Chim Farm; 1966 Aug; 105(8):563-9. PubMed ID: 6003361 [No Abstract] [Full Text] [Related]
6. Considerations for developing an antiarrhythmic agent: a perspective from the pharmaceutical industry. Antonaccio MJ Can J Cardiol; 1994 Apr; 10(3):325-6. PubMed ID: 8162528 [No Abstract] [Full Text] [Related]
7. [The responsibility of the pharmaceutical industry]. Andersen K Nord Med; 1975 Apr; 90(4):115. PubMed ID: 1134911 [No Abstract] [Full Text] [Related]
8. Comparative approaches to pharmaceutical price regulation in the European Union. Mrazek MF Croat Med J; 2002 Aug; 43(4):453-61. PubMed ID: 12187524 [TBL] [Abstract][Full Text] [Related]
9. Legal aspects of on-line pharmacy. de Clippele F Acta Chir Belg; 2004 Aug; 104(4):364-70. PubMed ID: 15469143 [No Abstract] [Full Text] [Related]
10. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
11. [Pharmaceutical brandnames]. Jacobs P Ned Tijdschr Geneeskd; 1975 May; 119(20):785-9. PubMed ID: 1161070 [No Abstract] [Full Text] [Related]
12. [Quality control in pharmaceutic industry]. de Oliveira E Hospital (Rio J); 1969 Feb; 75(2):543-61. PubMed ID: 5311212 [No Abstract] [Full Text] [Related]
13. The "Long" amendment. Provost GP Am J Hosp Pharm; 1967 Dec; 24(12):665. PubMed ID: 6073365 [No Abstract] [Full Text] [Related]
14. Some aspects of the preclinical safety of drugs produced by recombinant DNA technology: Japanese government regulatory position. Hayakawa T Prog Clin Biol Res; 1987; 235():15-29. PubMed ID: 3299390 [No Abstract] [Full Text] [Related]
15. Development of specifications for biotechnology products--perspective from Europe. Trouvin JH Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679 [No Abstract] [Full Text] [Related]
16. The pharmaceutical industry -- will Canada become a major research centre? Gray C Can Med Assoc J; 1981 Apr; 124(7):910, 914-5, 918 concl. PubMed ID: 7214290 [No Abstract] [Full Text] [Related]
17. Standing on your own feet. Apple WS J Am Pharm Assoc; 1974 Jun; 14(6):278-80. PubMed ID: 4840422 [No Abstract] [Full Text] [Related]
18. Toxicological aspects of European community legislation regarding new chemicals. Van Der Venne MT; Berlin A; Hunter WJ; Recht P Dev Toxicol Environ Sci; 1980; 8():473-8. PubMed ID: 7308047 [No Abstract] [Full Text] [Related]
19. No room for compromise. Bill C-22. McGillivray D CPJ; 1988 Feb; 121(2):88-9. PubMed ID: 10285967 [No Abstract] [Full Text] [Related]
20. The economic wisdom of regulating pharmaceutical "freebies". Fisher SH Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416 [No Abstract] [Full Text] [Related] [Next] [New Search]